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ABSTRACT 
Radiosynovectomy is a novel method of treatment for several acute and chronic inflammatory joint disorders. A 
small amount of a beta emitting radionuclide is injected into the affected joint delivering a radiation dose of 70 to 100 
Gy to the synovia. The proliferative tissue is destroyed, secretion of fluid and accumulation of inflammation causing 
cellular compounds stops and the joint surfaces become fibrosed, providing long term symptom relief. The radionuclides 
are injected in colloidal form so that they remain in the synovium and are not transported by lymphatic vessels causing 
radiation exposure to other organs. Complete reduction of knee joint swelling has been seen in above 40% and pain 
relief in 88% of patients. Wrist, elbow, shoulder, ankle and hip joints showed significant improvement in 50 60% and 
restoration of normal function and long term pain relief has been achieved in about 70% of small finger joints. In 
hemophilic arthropathies complete cessation of bleeding in about 60% and improved mobility in 75% of patients has 
been reported. © 2007 Biomedical Imaging and Intervention Journal. All rights reserved. 
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INTRODUCTION 
Joint disorders are relatively common in any society. 
Among the various forms of arthritis such as rheumatoid 
arthritis,  osteoarthritis,  villonodular  synovitis, 
hemophilic  arthropathies,  psoriatic  arthritis,  ankylosing 
spondylitis  and  gout,  acute  and  chronic  rheumatoid 
arthritis and hemophilic arthropathies are most common, 
causing  long  suffering  from  pain,  deformities  and 
disability. It has been estimated that nearly 30  million 
people  in  the  South  East  Asian  region  suffer  from 
rheumatoid  arthritis  alone  [1].  Conventional  long term 
treatment with various combinations of drugs can bring 
relief  in  many  cases.  However,  some  joints  need 
additional  local  therapy.  Mostly  corticosteroids  are 
injected  into  the  joints  to  suppress  the  inflammatory 
process localised in the synovium. 
In  some  cases,  surgery  is  also  performed. 
Radiosynovectomy (also known as radiosynoviorthesis) 
is  a  novel  method  of  treatment  for  such  joints.  The 
concept  of  radiosynovectomy  was  reported  earlier,  but 
Delbarre et al. in the year 1968 [2] introduced the term 
‘radio synoviorthesis’ for the first time and also reported 
their  clinical  experience.  Radisynovectomy  or 
radiosynoviorthesis  is  defined  as  the  restoration  of 
inflamed and damaged synovial membrane of the joints 
after  application  of  radionuclides  (radioisotopes).  The 
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beta  rays  emitted  by  the  radionuclides  are  used  to 
effectively  control  the  inflammatory  process  of  the 
synovial membrane and the technique is indicated as an 
alternative therapy to early surgical synovectomy. 
The purpose of this article is to describe the method 
and  assess  the  impact  of  this  novel  technique  in  the 
overall  management  of  rheumatoid  arthritis  and 
hemophilic arthropathies. 
MAGNITUDE OF THE PROBLEM 
Rheumatoid  arthritis  (RA)  is  the  most  common 
chronic  inflammatory  disease  of  joints.  It  affect  more 
than 1% of the population. This disease is more prevalent 
in women with a preponderance of 3:1 over men. It has 
been estimated that in Malaysia 0.22 million patients are 
suffering from this disease. It usually starts in fourth and 
fifth  decade  of  life.  However  no  age  group  in  spared 
from this crippling disease. 80% of patients developing 
the disease are found to be between 35 to 50 years of age. 
The causes of RA are not known, but there is strong 
evidence of involvement of cellular and humoral immune 
systems. This may be genetically predetermined as the 
incidence  of  sero positive  RA  is  more  common  in  the 
population  with  HLA DR4  (60%)  than  in  normal 
controls  (15%).  It  has  also  been  suggested  that  RA 
manifests in response to certain environmental factors, 
and hormonal disturbances may play a role but the actual 
mechanism  is  not  known.  In  many  cases  RA  shows  a 
“tumour  like  proliferation”  with  rapidly  growing 
synovial membrane and pannus formation which behaves 
similar to a locally invasive tumour. 
Clinically  rheumatoid  arthritis  presents  like  a 
chronic multi system disease with a variety of systemic 
manifestations  but  a  characteristic  feature  is  the 
persistent  inflammatory  synovitis.  Most  commonly 
involved  joints  are  proximal  inter phalangeal  joints, 
metacarpophalangeal joints, wrist and knee joints. In the 
long  run  synovial  inflammation  causes  cartilage 
destruction,  bone  erosion  and  joint  deformity  with 
marked functional impairment. 
Hemophilia is a common bleeding disorder in South 
East Asian countries. The incidence is more than 0.01% . 
More than half of the patients with this disorder suffer 
from arthropathy which cripples life at an early age. 
The cause of hemophilia is a deficiency of clotting 
factors  VIII  (Hemophilia  A)  and  IX  (Hemophilia  B). 
Inadequate  replacement  of  factor  VIII  and  IX,  lack  of 
patient education, lack of physician education regarding 
simple  techniques  (application  of  ice  or  ice  packs, 
immobilisation of affected joints, use of slings), lack of 
physiotherapy  and  lack  of  new  therapy  methods  like 
radiation synovectomy have contributed to the fact that 
more  than  50%  of  these  patients  suffer  from  physical 
disability and crippling arthropathy. 
PRINCIPLES OF THE THERAPY 
Radioactive isotopes which emit beta rays are used 
for Radiosynovectomy. The radionuclides in the form of 
colloids, on reaching the joint cavity are recognised as 
foreign  bodies  by  the  outermost  cellular  layer  of  the 
synovial membrane and are phagocytosed by these cells. 
Autoradiographic  investigations  show  that  Yttrium 
colloids quickly enter the superficial layers and also to 
some extent the deeper layers of the synovial membrane 
but  very  little  reaches  the  bones  [3,  4].  Due  to  the 
selective  radiation  of  the  synovial  membrane,  there  is 
necrosis of the cells and reduction in the inflammatory 
cellular proliferation. Arthroscopic examination shows a 
reduction in the number and size of the synovial villi and 
reduction in the hyperemic reaction [5, 6]. Later there is 
progressive fibrosis of the synovial stroma, the vessels 
and rarely, mild diffuse damage to the bones of the joint 
[7].  There  is  also  prevention  of  the  filtration  and 
reabsorption of the synovial fluid. 
There is complete disappearance of the mononuclear 
infiltration in the synovial membrane after a few months 
and  the  synovial  membrane  is  fibrosed  [8].  Further 
destruction  of  the  joint  cavity  otherwise  caused  by 
continuous immunological reactions is prevented. Since 
the  fibrotic  tissue  replacing  the  synovial  membrane 
cannot react to the immunological stimulation, there is 
no  recurrence  of  the  inflammatory  process  and  a  long 
term remission is achieved. 
INDICATIONS 
The basic understanding of treatment of rheumatoid 
arthritis  is  that  it  is  a  systemic  disease  and  therefore, 
should  be  treated  systemically.  Radiosynovectomy  is 
indicated  when  disease  modifying  therapy  has  been 
given for 6 months and in spite of that some joints are 
still affected and any increase of drug dosage may have 
serious side effects on the patient. Any exception from 
these basic principles of treatment can be made only by 
an  expert  in  the  field  and  in  consultation  with 
rheumatologist,  orthopedician  or  the  surgical 
rheumatologist.  However,  if  radiosynovectomy  is 
performed  early  in  course  of  the  disease,  the  overall 
result  and  prognosis  of  the  treated  joint  appears  to  be 
better. Although best results are obtained in Steinbrocker 
stage I and II of the polyarthritis [9], radiosynovectomy 
is effective even in the later stages of the disease. The 
main  indications  for  radiosynovectomy  are:  acute 
rheumatoid  arthritis,  chronic  polyarthritis,  psoriatic 
arthritis,  anklylosing  spondylitis  with  peripheral  joint 
involvement, pigmented villonodular synovitis (6 weeks 
after  surgery)  haemarthrosis  in  hemophilia  (not  during 
active  bleeding  phase)  and  activated  arthrosis  or 
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RADIONUCLIDES USED IN RADIOSYNOVECTOMY 
In early  studies radionuclide gold 198 in colloidal 
form was used. However, due to its gamma component 
leading  to  unwanted  whole  body  radiation  exposure 
combined with spread to lymph nodes and liver, it has 
been  almost  abandoned.  There  are  a  variety  of 
radionuclides  available  now  which  are  suitable  for 
radiosynovectomy. The type of radionuclide to be used is 
determined  by  the  size  of  the  joint  to  be  treated.  The 
lesser range (weaker) beta rays are used in smaller joints 
like Erbium 169 for finger joints. Similarly the medium 
range beta rays of Rhenium 186, Phosphorus 32, etc. are 
used for larger joints (wrist, elbow, shoulder, ankle and 
hip joints) while the high energy beta rays of Yttrium 90 
with tissue penetration of 3 to 11 mm are used for knee 
joints.  In  recent  years  several  other  radionuclides  like 
Holmium 166,  Rhenium 188,  Samarium 153,  etc.  have 
successfully been introduced [10 18]. 
DOSE CONSIDERATIONS 
It  is  difficult  to  exactly  determine  the  required 
dosage. The absorbed dose is not only dependent on the 
type of the radionuclide and the amount of activity (MBq 
/ mCi) used but also on various other factors like the size 
of  joint  cavity,  synovial  thickness,  distribution  of  the 
colloids  in  the  joint  fluid  (water,  gelatinous  or 
hemorrhagic) and the inflammatory activity of the joints. 
A typical dose of 185 MBq (5mCi) of Yttrium (Yt 90) is 
used for knee joints. Approximately 100 Gy per 100 gm 
synovial  tissue  should  be  absorbed,  to  have  optimal 
effect. 
SIDE EFFECTS 
If done properly, no side effects have been observed. 
Infection  of  the  joint  is  very  rare  (one  in  35,000)  in 
comparison  to  intra articular  corticosteroid  injections. 
This is because of the intense beta radiation emitted by 
the high concentration of radioactive material in the joint 
killing  all  the  bacteria.  Temporary  radiation  or  crystal 
synovitis,  thrombosis  due  to  immobilisation  and 
lymphoedema may occur. 
PRACTICAL GUIDELINES 
Ideally there should be close cooperation with the 
nuclear  medicine  physician,  rheumatologist  and 
orthopedician  who  would  consider  the  indication  and 
refer the patients for the procedure. It should be ensured 
that  the  basic  therapy  for  rheumatic  disease  has  been 
given for 6 months and surgical options for early or late 
synovectomy, tendon reconstruction (in case of tendon 
rupture), nerve decompression, etc. have been taken into 
consideration. 
After  taking  the  history  and  careful  clinical 
examination  of  the  patient,  the  risks,  side  effects  and 
possible  complications  of  the  procedure  have  to  be 
explained to the patient and a written consent has to be 
obtained. 
In addition to the X ray films of the affected joints, 
two  more investigations, namely arthrosonography and 
scintigraphy, may also be considered to obtain optimal 
results. 
ARTHROSONOGRAPHY  
It  is  sometimes  possible  to  miss  the  presence  of 
problematic  Baker’s  cyst  of  the  knee  joint  during  the 
clinical  examination.  If  radiosynovectomy  of  the  knee 
joint  with  Baker’s  cyst  is  performed,  it  may  lead  to 
rupture  of  the  cyst  as  a  consequence  of  inflammatory 
reaction [19]. This is a fatal complication and must be 
avoided. As such Baker’s cyst of the knee joint with high 
risk  of  rupture  is  taken  as  a  contraindication  for 
radiosynovectomy.  Fortunately  Baker’s  cyst  can  be 
definitely diagnosed by arthrosonography. In a study of 
980 cases of  knee joints treated by radiosynovectomy, 
Baker’s cyst was detected in 25% of the knee joints [20]. 
In  the  presence  of  a  firm  painful  Baker’s  cyst  it  is 
advisable to aspirate the cyst under ultrasound guidance 
and  instill  cortisone  at  least  three  days  prior  to 
radiosynovectomy.  So  arthrosonography  is  absolutely 
necessary prior to radiosynovectomy of the knee joints. 
But  it  may  also  be  required  in  case  of  shoulder  joint 
because it provides information of the condition inside 
the joint (effusion, rotator cuff rupture of the shoulder, 
sub  deltoid  bursitis  etc.)  and  also  about  the  peripheral 
structures  (tenosynovitis,  enthesitis  etc.).  These  details 
and use of an intensifier help to increase the accuracy of 
intra articular administration of the radiopharmaceutical. 
JOINT SCINTIGRAPHY  
The usual skeletal scintigraphy is performed 3 hours 
after injection of the radiopharmaceutical (usually 99m 
Tc MDP / HDP). In soft tissue scintigraphy, images have 
to be taken 5 minutes post injection at a time when most 
of the radiopharmaceutical is still in the blood stream and 
in soft tissues. The hyperemic areas in synovitis seen as 
increased  concentration  of  the  radiopharmaceutical  are 
highly suggestive of inflammatory activity at the joint. 
This  procedure  gives  fairly  accurate  information  about 
the  polyarticular  involvement  and  the  intensity  of 
synovitis which correlate well with the degree and the 
intensity  of  pain,  even  months  before  any  radiological 
changes are seen in the joint. For example, it is often 
possible to identify the particular tendons or joints of the 
middle foot causing the actual pain to the patient who 
sometimes may not be able to pinpoint exactly the site of 
involvement.  The  soft  tissue  scintigraphic  images  also 
help to identify the suitable joints, which will respond to 
radiosynovectomy [21]. BK Das et al. Biomed Imaging Interv J 2007; 3(4):e45    4 
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DOSE INJECTION 
Since even a slight extra  articular extravasation of 
the radioactive material can lead to tissue necrosis, it is 
very important to be perfect in the injection technique. 
All  joints  with  the  exception  of  knee  joints  must  be 
injected  only  under  radiological  guidance.  A  x ray 
machine  called  C arm  which  is  otherwise  used  for 
various  radiological  procedures  can  be  used  for  the 
purpose.  
In  all  joints  (specially  the  small  finger  joints) 
arthrographic orientation of the joint space and the ideal 
position for the needle placement should be done before 
starting the procedure. 
After the procedure a distribution scintigram of the 
joint wherever possible may be performed to document 
the distribution of the radionuclide in the joint. 
It is advisable to inject a corticosteroid preparation 
along with the radio nuclide for following benefits: 
●  Radiation  synovitis  with  effusion  (knee  joint) 
can be avoided. 
●  The  inflammatory  component  will  subside 
effectively through the corticosteroid so that the 
radionuclide therapy can be more effective. 
●  In the wrist joint, it helps Rhenium (Rh 186) to 
spread well in the distally located inter carpal 
compartments. 
●  It helps to relieve the patients of the symptoms 
immediately  and  thereby  bridge  the  time  till 
effects  of  intense  radiation  from  the 
radionuclide sets in. 
After  the  radiosynovectomy,  the  joint  should  be 
immobilised for 48 hours with help of a splint. It will 
help to prevent the lymphatic spread and reduce leakage 
rate if the joint is given rest for about a week [22]. 
It  takes  up  to  3  months  to  get  the  full  effects  of 
radiosynovectomy.  Symptoms  may  persist  during  this 
period  and  sometimes  there  may  also  be  an  effusion 
which needs to be drained during the follow up after 3 or 
4  months.  If  corticosteroid  has  been  injected 
simultaneously,  patient  may  remain  free  of  complaints 
even during the initial period till the radiosynovectomy 
becomes effective. 
RESULT AND DISCUSSION 
A large number of procedures using Yittrium 90 for 
knee  joints  have  been  performed  worldwide. 
Improvement rates ranging from 40 to 100% have been 
reported [23 27]. In two years follow up of patients, knee 
joint swellings were reduced almost completely in 38%, 
pain  relief  was  achieved  in  88%  and  stretching 
deficiency  corrected  in  71%  of  the  cases  [22].  Some 
reports quote an improvement rate of 85% after 3 4 years 
[25]. Rhenium (Re 186) is used for middle sized joints. 
Good to excellent results are seen in 60 80% of the cases 
in hand, elbow, shoulder, ankle and hip joints [28]. Good 
to very good results have been reported in 83% of the 
elbow joints [29, 30]. 
Erbium  (Er 169)  is  used  in  small  joints  of  the 
fingers. Good to very good results leading to restoration 
of normal function has been reported in 54.6% in a study 
consisting 1261 finger joints [31, 32]. 
Similar results were reported by Boussiana et al. in a 
double blind study conducted involving PIP joints in 35 
patients suffering from chronic polyarthritis who did not 
respond to intra articular corticosteroid injections [32]. 
Good to excellent results were seen in 71.5% of cases in 
relation to pain relief and joint mobility 6 months after 
radiosynovectomy.  After  one  year  good  to  excellent 
results  were  seen  in  79.4%,  with  no  improvement  in 
20.6% of cases. The X ray findings of the joints treated 
by radiosynovectomy showed no changes after 1 year as 
against  those  in  placebo  group  (physiological  NaCl) 
which showed reduction in the joint space. In addition, 
there was fibrosis and absence of inflammatory changes 
in those joints treated with Er 169 whereas persistence of 
all histological changes of rheumatoid arthritis was seen 
in the placebo group [33].  
Since  the  radionuclides  are  applied  in  form  of 
colloids of appropriate size, they remain mostly within 
the joints. There is no significant radiation exposure to 
other  organ  or  parts  of  the  body.  Being  beta  emitters, 
they also don’t pose any radiation to the environment, so 
the procedure can be performed on ambulatory patients. 
If  adequate  response  has  not  been  achieved  or 
recurrence of the disease occurs it may be advisable to 
repeat the procedure, preferably 6 months after the first 
treatment. Favourable results have been reported after re 
radiosynovectomy  of  the  knee  joints  in  cases  of 
rheumatoid arthritis.  
CONCLUSION 
Radiosynovectomy  is  an  effective  alternative 
therapeutic  approach  in  many  conditions  needing 
additional  treatment  of  individual  joints.  It  has  been 
found to be cost effective in providing long term relief of 
pain and deformity. 
The  number  of  centres  performing 
radiosynovectomy is increasing all over the  world and 
reports  of  new  indications  like  application  in 
complication  of  total  knee  joint  prosthesis  leading  to 
effusion is increasingly seen in literature [34]. There is 
no radiation risk and the procedure can be performed on 
an outpatient basis. 
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